[go: up one dir, main page]

PE20030350A1 - Solvatos de clorhidrato de lercanipidina y novedosas formas cristalinas de clorhidrato de lercanidipina que se obtienen a partir de dichos solvatos - Google Patents

Solvatos de clorhidrato de lercanipidina y novedosas formas cristalinas de clorhidrato de lercanidipina que se obtienen a partir de dichos solvatos

Info

Publication number
PE20030350A1
PE20030350A1 PE2002000716A PE2002000716A PE20030350A1 PE 20030350 A1 PE20030350 A1 PE 20030350A1 PE 2002000716 A PE2002000716 A PE 2002000716A PE 2002000716 A PE2002000716 A PE 2002000716A PE 20030350 A1 PE20030350 A1 PE 20030350A1
Authority
PE
Peru
Prior art keywords
solvates
hydrochloride
lercanidipine hydrochloride
refers
lercanipidine
Prior art date
Application number
PE2002000716A
Other languages
English (en)
Inventor
Fausto Bonifacio
Amadeo Leonardi
Iasi Gianluca De
Original Assignee
Recordati Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recordati Ireland Ltd filed Critical Recordati Ireland Ltd
Publication of PE20030350A1 publication Critical patent/PE20030350A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A CLORHIDRATO DE LERCANIDIPINA [METIL 1,1,N-TRIMETIL-N-(3,3-DIFENILPROPIL)-2-AMINOETIL-1,4-DIHIDRO-2,6-DIMETIL-4-(3-NITROFENIL)PIRIDIN-3,5-DICARBOXILATO] CON SOLVENTES ORGANICOS QUE SE SELECCIONAN DE CLORURO DE METILENO, ACETONA, ANISOL, TETRAHIDROFURANO, METIL-TERBUTIL-ETER, ISOPROPANOL, ENTRE OTROS. LA FORMA CRISTALINA CON CLORURO DE METILENO PRESENTA DIFRACCION DE RAYOS X A LA LONGITUD DE ONDA KO CON UNA d(A) DESDE 2,04 A HASTA 6,6 A; UNA INTENSIDAD RELATIVA DE 29% A 100% Y UN ANGULO (2 0) DESDE 13,4 A 44,4. EL SOLVATO DE FORMA A PRESENTA ASIMISMO RESULTADOS DE DIFRACCION DE RAYO X A LA LONGITUD DE ONDA KO CON UNA d(A) DESDE 2,86 A HASTA 17,4 A, UNA INTENSIDAD RELATIVA DE 29% A 100% Y UN ANGULO (2 0) DESDE 5,1 A 31,3. EL CLORHIDRATO DE LERCANIDIPINA SE PRESENTE EN FORMA MICRONIZADA Y LA GRANULOMETRIAPROMEDIO DE DICHA FORMA ES DE D(50%) 2-8 um, D(90%) MENOR A 15 um. SE REFIERE TAMBIEN A COMPOSICIONES FARMACEUTICAS QUE CONTIENEN ENTRE 1,1 mg A 400mg DE UN AGENTE ACTIVO, DICHAS COMPOSICIONES COMPRENDEN CLORHIDRATO DE LERCANIDIPINA CRISTALINO DE LA FORMA III Y IV. SE REFIERE ADEMAS A UN PROCEDIMIENTO PARA LA PREPARACION
PE2002000716A 2001-08-06 2002-08-06 Solvatos de clorhidrato de lercanipidina y novedosas formas cristalinas de clorhidrato de lercanidipina que se obtienen a partir de dichos solvatos PE20030350A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2001MI001727A ITMI20011727A1 (it) 2001-08-06 2001-08-06 Solvati della lercanidipina cloridrato e nuove forme cristalline della lercanidipina cloridrato ottenute da essi

Publications (1)

Publication Number Publication Date
PE20030350A1 true PE20030350A1 (es) 2003-06-06

Family

ID=11448246

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000716A PE20030350A1 (es) 2001-08-06 2002-08-06 Solvatos de clorhidrato de lercanipidina y novedosas formas cristalinas de clorhidrato de lercanidipina que se obtienen a partir de dichos solvatos

Country Status (21)

Country Link
EP (1) EP1423367B1 (es)
JP (1) JP2005502648A (es)
KR (1) KR100912664B1 (es)
CN (1) CN100494175C (es)
AR (1) AR037230A1 (es)
AT (1) ATE294162T1 (es)
AU (1) AU2002331390B2 (es)
BR (1) BR0211738A (es)
DE (1) DE60203919D1 (es)
EA (1) EA200400279A1 (es)
ES (1) ES2209684T1 (es)
HR (1) HRP20040157A2 (es)
HU (1) HUP0401161A3 (es)
IL (2) IL153916A0 (es)
IT (1) ITMI20011727A1 (es)
MX (1) MXPA04001073A (es)
NO (1) NO20040479L (es)
PE (1) PE20030350A1 (es)
PL (1) PL369449A1 (es)
UY (1) UY27409A1 (es)
WO (1) WO2003014085A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100651212B1 (ko) 2004-10-27 2006-12-01 제일약품주식회사 무정형 레르카니디핀의 제조방법
AR052918A1 (es) 2005-02-25 2007-04-11 Recordati Ireland Ltd Clorhidrato de lercanidipina amorfo
KR20080048065A (ko) 2005-09-16 2008-05-30 그렌마크 파머수티칼스 엘티디. 다형 형태의 염산 레르카니디핀 및 이것의 제조방법
WO2008107797A2 (en) * 2007-03-05 2008-09-12 Actavis Group Ptc Ehf Lercanidipine hydrochloride polymorphs and an improved process for preparation of 1,1,n-trimethyl-n-(3,3-diphenylpropyl)-2-aminoethyl acetoacetate
WO2008136394A1 (ja) * 2007-04-27 2008-11-13 Ajinomoto Co., Inc. ラクタム化合物の製造方法及びその製造中間体
EP2585051B2 (en) 2010-06-23 2020-04-08 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical oral dosage forms comprising lercanidipine and enalapril and their pharmaceutically acceptable salts
EA023996B1 (ru) 2010-12-24 2016-08-31 КРКА, д.д., НОВО МЕСТО Гомогенные фармацевтические пероральные лекарственные формы, содержащие лерканидипин и эналаприл или их фармацевтически приемлемые соли совместно с органической кислотой

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8403866D0 (en) * 1984-02-14 1984-03-21 Recordati Chem Pharm Diphenylalkylaminoalkyl esters
US5912351A (en) * 1995-05-12 1999-06-15 Recordati, S.A. Chemical And Pharmaceutical Company Anhydrous 1,4-Dihydropyridines and salts thereof

Also Published As

Publication number Publication date
EP1423367A1 (en) 2004-06-02
CN100494175C (zh) 2009-06-03
ATE294162T1 (de) 2005-05-15
BR0211738A (pt) 2004-09-28
KR20040030932A (ko) 2004-04-09
EA200400279A1 (ru) 2004-06-24
UY27409A1 (es) 2003-03-31
DE60203919D1 (de) 2005-06-02
HRP20040157A2 (en) 2004-08-31
IL153916A (en) 2008-07-08
WO2003014085A1 (en) 2003-02-20
AR037230A1 (es) 2004-11-03
AU2002331390B2 (en) 2008-06-05
KR100912664B1 (ko) 2009-08-17
HUP0401161A3 (en) 2009-04-28
CN1538958A (zh) 2004-10-20
ES2209684T1 (es) 2004-07-01
JP2005502648A (ja) 2005-01-27
PL369449A1 (en) 2005-04-18
IL153916A0 (en) 2003-07-31
HUP0401161A2 (hu) 2004-09-28
MXPA04001073A (es) 2005-02-17
NO20040479L (no) 2004-02-03
EP1423367B1 (en) 2005-04-27
ITMI20011727A0 (it) 2001-08-06
ITMI20011727A1 (it) 2003-02-06

Similar Documents

Publication Publication Date Title
RU2218922C2 (ru) Соединения, имеющие в своей структуре фрагмент производного глюкуроновой кислоты и фрагмент производного глюкозамина, способы получения этих соединений и применение этих соединений
CA2385890A1 (en) Controlled release compositions comprising nimesulide
NO20085077L (no) Nye forbindelser
KR970706837A (ko) 약학 조성물 (pharmaceutical compositions)
AR033859A1 (es) Inhibidores de la metaloproteinasa de la matriz
AU5669398A (en) Novel cyclosporin derivatives, method of preparation and pharmaceutical compositions containing them
WO2005118166A3 (en) Pharmaceutical composition containing irbesartan
CA2294337A1 (en) Preparation of pharmaceutical compositions
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
AP1776A (en) Reconstitutable parenteral composition containing a cox-2 inhibitor.
PE20030350A1 (es) Solvatos de clorhidrato de lercanipidina y novedosas formas cristalinas de clorhidrato de lercanidipina que se obtienen a partir de dichos solvatos
RU2002100058A (ru) Кристаллические производные 1-метилкарбапенема
EP0992509A3 (en) Novel macrolide derivatives
KR910016332A (ko) 수난용성 약제를 함유하는 약학 조성물
AR009651A1 (es) Composicion solubilizante/estabilizante anhidra, emulsionable o microemulsionable en agua, para la solubilizacion de los derivados hidrofobosde n-sulfonil indolina, composicion farmaceutica microemulsionable o emulsionable en medio acuoso, y capsulas farmaceuticas, particularmente blandas
NO20026081L (no) Nye forbindelser
BR0005392A (pt) Composição de dhea e processo
CY1105168T1 (el) Διφασικη συνθεση με τραμαδολη
HUP9902559A2 (hu) Paracetamolt és drotavenint tartalmazó gyógyszerkészítmény és eljárás előállítására
PT97164A (pt) Processo para a estabilizacao de uma preparacao que contenham o composto 4-etil-2-hidroxi-imino-5-nitro-3-hexenamida e de composicoes farmaceuticas que o contenham
EP2066301B1 (en) Injectable pharmaceutical nimesulide solutions
NO20055016L (no) Farmasoytisk sammensetning som fast doseringsform og fremgangsmate for fremstilling derav
CS235524B2 (en) Method of levonantradole derivatives solubilization
KR950005312A (ko) 간질환 치료 및 간기능 개선용 의약조성물
KR960021036A (ko) 콜치신을 유효성분으로 함유하는 항간독성 조성물 및 그 제조방법

Legal Events

Date Code Title Description
FD Application declared void or lapsed